ACCESS SOLUTIONS

Post-Trial Supply

Tanner offers pharmaceutical companies a lower-cost alternative to bridge treatment for trial patients until a medicine is commercially available.

HOW IT WORKS

Consider continuity

When a clinical trial has finished, pharmaceutical companies are typically obligated to continue supplying patients with the investigational medicine until it is commercially available. Additionally, if a medicine has failed its clinical trial or the pharmaceutical company has decided to discontinue development, there may still be obligations to supply the study medicine for patients who benefited. As a result, pharmaceutical companies continue to incur costs and utilize resources until trial sites are closed. Tanner offers pharmaceutical companies a lower-cost alternative to bridge treatment for trial patients until a medicine is commercially available.

Contact Us

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.